Dr. Christopher H. Lieu
Claim this profileUniversity of Colorado Hospital
Studies Colorectal Cancer
Studies Cancer
10 reported clinical trials
39 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
MLH1 positive
2Cancer
Stage IV
CD4+ positive
Stage III
Affiliated Hospitals
Clinical Trials Christopher H. Lieu is currently running
Nivolumab + Standard Treatment
for Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Recruiting1 award Phase 2
SAR444881 + Standard Therapies
for Advanced Cancer
This trial tests a new drug, SAR444881, alone and with other treatments in advanced cancer patients who haven't responded to other therapies. The goal is to find the best dose and combination to treat these patients effectively.
Recruiting1 award Phase 1 & 27 criteria
More about Christopher H. Lieu
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Christopher H. Lieu has experience with
- Pembrolizumab
- Cetuximab
- Nivolumab
- Binimetinib
- BND-22
- Ipilimumab
Breakdown of trials Christopher H. Lieu has run
Colorectal Cancer
Cancer
Tumors
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher H. Lieu specialize in?
Christopher H. Lieu focuses on Colorectal Cancer and Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Christopher H. Lieu currently recruiting for clinical trials?
Yes, Christopher H. Lieu is currently recruiting for 4 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Christopher H. Lieu has studied deeply?
Yes, Christopher H. Lieu has studied treatments such as Pembrolizumab, Cetuximab, Nivolumab.
What is the best way to schedule an appointment with Christopher H. Lieu?
Apply for one of the trials that Christopher H. Lieu is conducting.
What is the office address of Christopher H. Lieu?
The office of Christopher H. Lieu is located at: University of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.